Moreover, after anti-EGFR therapy, wild-type CRC cells acquire mutations in RAS, BRAF, PIK3CA, HER2, FGFR1, PDGFRA,and MAP2K1 solely or in combination24,25. Here, ERBB2 is linked to colorectal carcinoma.